Poseida Historical Income Statement

PSTX Stock

USD 9.31 0.02 0.21%

Historical analysis of Poseida Therapeutics income statement accounts such as Selling General Administrative of 39.3 M, Total Revenue of 67.9 M, Other Operating Expenses of 188.3 M or Research Development of 164.6 M can show how well Poseida Therapeutics performed in making a profits. Evaluating Poseida Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Poseida Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Poseida Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Poseida Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poseida Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

About Poseida Income Statement Analysis

Poseida Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Poseida Therapeutics shareholders. The income statement also shows Poseida investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Poseida Therapeutics Income Statement Chart

At this time, Poseida Therapeutics' Interest Expense is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 112.3 K in 2024, whereas Net Loss is likely to drop (60.5 M) in 2024.

Selling General Administrative Other Operating Expenses Operating Income Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Poseida Therapeutics. It is also known as Poseida Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Poseida Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Poseida Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Poseida Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Poseida Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poseida Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.At this time, Poseida Therapeutics' Interest Expense is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 112.3 K in 2024, whereas Net Loss is likely to drop (60.5 M) in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	4.6M	5.2M	5.6M	3.4M
Total Operating Expenses	172.6K	190.4M	194.2M	203.9M

Reconciled Depreciation Total Operating Expenses

Poseida Therapeutics income statement Correlations

	Income Tax Expense	Tax Provision	Net Interest Income	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Cost Of Revenue	Non Operating Income Net Other
Income Tax Expense		0.07	-0.08	0.51	0.37	0.1	0.04	0.34	-0.5	0.16	0.19	0.31	0.23	0.32	-0.25	-0.53	0.23	-0.56	0.04	-0.54
Tax Provision	0.07		-0.87	0.74	0.73	0.77	0.11	0.74	-0.57	-0.78	-0.74	0.72	-0.72	0.72	0.88	-0.58	-0.18	-0.57	0.43	0.36
Net Interest Income	-0.08	-0.87		-0.69	-0.88	-0.77	0.32	-0.88	0.83	0.82	0.77	-0.89	0.75	-0.89	-0.88	0.82	0.05	0.8	-0.82	-0.28
Depreciation And Amortization	0.51	0.74	-0.69		0.58	0.4	-0.1	0.57	-0.64	-0.69	-0.65	0.55	-0.61	0.56	0.56	-0.65	0.02	-0.66	0.36	0.29
Selling General Administrative	0.37	0.73	-0.88	0.58		0.88	-0.17	1.0	-0.91	-0.47	-0.38	1.0	-0.35	1.0	0.67	-0.92	0.23	-0.91	0.76	-0.03
Total Revenue	0.1	0.77	-0.77	0.4	0.88		0.21	0.9	-0.62	-0.36	-0.29	0.89	-0.28	0.89	0.73	-0.63	0.12	-0.62	0.52	0.07
Gross Profit	0.04	0.11	0.32	-0.1	-0.17	0.21		-0.14	0.48	0.41	0.38	-0.19	0.38	-0.19	-0.08	0.44	-0.07	0.43	-0.73	-0.06
Other Operating Expenses	0.34	0.74	-0.88	0.57	1.0	0.9	-0.14		-0.89	-0.46	-0.38	1.0	-0.35	1.0	0.69	-0.9	0.22	-0.89	0.75	-0.01
Operating Income	-0.5	-0.57	0.83	-0.64	-0.91	-0.62	0.48	-0.89		0.5	0.42	-0.9	0.39	-0.9	-0.53	1.0	-0.26	1.0	-0.85	0.07
Net Income From Continuing Ops	0.16	-0.78	0.82	-0.69	-0.47	-0.36	0.41	-0.46	0.5		0.99	-0.48	0.99	-0.48	-0.78	0.49	0.35	0.47	-0.6	-0.52
Ebit	0.19	-0.74	0.77	-0.65	-0.38	-0.29	0.38	-0.38	0.42	0.99		-0.4	1.0	-0.39	-0.73	0.4	0.46	0.38	-0.53	-0.49
Research Development	0.31	0.72	-0.89	0.55	1.0	0.89	-0.19	1.0	-0.9	-0.48	-0.4		-0.37	1.0	0.69	-0.9	0.21	-0.9	0.79	0.0
Ebitda	0.23	-0.72	0.75	-0.61	-0.35	-0.28	0.38	-0.35	0.39	0.99	1.0	-0.37		-0.37	-0.73	0.37	0.48	0.35	-0.52	-0.49
Total Operating Expenses	0.32	0.72	-0.89	0.56	1.0	0.89	-0.19	1.0	-0.9	-0.48	-0.39	1.0	-0.37		0.69	-0.91	0.22	-0.9	0.78	-0.01
Reconciled Depreciation	-0.25	0.88	-0.88	0.56	0.67	0.73	-0.08	0.69	-0.53	-0.78	-0.73	0.69	-0.73	0.69		-0.52	-0.04	-0.5	0.57	0.57
Income Before Tax	-0.53	-0.58	0.82	-0.65	-0.92	-0.63	0.44	-0.9	1.0	0.49	0.4	-0.9	0.37	-0.91	-0.52		-0.26	1.0	-0.82	0.09
Total Other Income Expense Net	0.23	-0.18	0.05	0.02	0.23	0.12	-0.07	0.22	-0.26	0.35	0.46	0.21	0.48	0.22	-0.04	-0.26		-0.27	0.14	0.21
Net Income	-0.56	-0.57	0.8	-0.66	-0.91	-0.62	0.43	-0.89	1.0	0.47	0.38	-0.9	0.35	-0.9	-0.5	1.0	-0.27		-0.8	0.11
Cost Of Revenue	0.04	0.43	-0.82	0.36	0.76	0.52	-0.73	0.75	-0.85	-0.6	-0.53	0.79	-0.52	0.78	0.57	-0.82	0.14	-0.8		0.1
Non Operating Income Net Other	-0.54	0.36	-0.28	0.29	-0.03	0.07	-0.06	-0.01	0.07	-0.52	-0.49	0.0	-0.49	-0.01	0.57	0.09	0.21	0.11	0.1

Click cells to compare fundamentals

Poseida Therapeutics Account Relationship Matchups

Poseida Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	3.6M	3.5K	3.4K	6.4M	8.7M	9.1M
Net Income Applicable To Common Shares	(86.5M)	(129.8M)	(125.0M)	(64.0M)	(57.6M)	(60.5M)
Income Tax Expense	6.1M	(2.6M)	(4.5M)	544K	107K	112.4K
Net Interest Income	(3.6M)	(3.5M)	(3.4M)	(6.4M)	(8.7M)	(8.2M)
Depreciation And Amortization	10.4M	2.6M	4.6M	5.2M	5.6M	4.7M
Selling General Administrative	18.5M	23.0K	35.9K	37.5M	37.4M	39.3M
Other Operating Expenses	78.9M	126.5K	172.6K	190.4M	179.4M	188.3M
Operating Income	(85.5M)	(126.5K)	(141.4K)	(59.9M)	(129.5M)	(123.0M)
Net Income From Continuing Ops	(86.5M)	(129.8M)	(125.0M)	(64.0M)	(123.4M)	(129.6M)
Ebit	(85.5M)	(148.1M)	(121.6M)	(59.9M)	(114.7M)	(120.4M)
Research Development	60.4M	103.5K	136.7K	152.9M	156.8M	164.6M
Ebitda	(75.1M)	(145.5M)	(117.1M)	(54.8M)	(109.0M)	(114.5M)
Total Operating Expenses	78.9M	126.5K	172.6K	190.4M	194.2M	203.9M
Reconciled Depreciation	1.2M	2.6M	4.6M	5.2M	5.6M	3.4M
Income Before Tax	(86.5M)	(129.8K)	(125.0K)	(63.5M)	(123.3M)	(117.2M)
Total Other Income Expense Net	(994K)	(129.6M)	16.4M	(3.5M)	6.2M	6.5M
Net Income	(92.6M)	2.5M	4.4M	(64.0M)	(123.4M)	(117.3M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Poseida Historical Income Statement

About Poseida Income Statement Analysis

Poseida Therapeutics Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Poseida Therapeutics income statement Correlations

Poseida Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Poseida Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Poseida Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Operating Income

Income Before Tax	- 0.92	Selling General Administrative
Income Before Tax	- 0.91	Total Operating Expenses
Net Income	- 0.91	Selling General Administrative
Operating Income	- 0.91	Selling General Administrative
Net Income	- 0.9	Total Operating Expenses
Net Income	- 0.9	Research Development